<DOC>
	<DOCNO>NCT00196950</DOCNO>
	<brief_summary>The purpose study evaluate safety , reactogenicity , immunogenicity persistence three year administration one dose MenACWY conjugate vaccine give young adult age 18-25 year .</brief_summary>
	<brief_title>Study Evaluate Meningococcal Serogroups A , C , W-135 , Y Conjugate Vaccine When Given 1 Dose Healthy Subjects Aged 18-25 Years</brief_title>
	<detailed_description>Administration candidate vaccine active control ( Mencevax™ ACWY ) do open manner . The study consist vaccination phase subject receive one vaccine dose ( GSK 's MenACWY conjugate vaccine Mencevax™ ACWY vaccine ) 3 year follow-up . There total 7 visit doctor : 2 , 7 30 day vaccination ( vaccination phase ) well 12 , 24 36 month vaccination ( follow-up phase ) . 7 blood sample take : one visit .</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criterion : Healthy male female , include , 18 25 year age time vaccination . Written inform consent obtain . Subject previously complete routine childhood vaccination best his/her knowledge . Female subject nonchildbearing potential , abstinent , use adequate contraception . Exclusion criterion : Previous vaccination OR history OR exposure within previous 12 month , meningococcal serogroup A , C , W135 Y disease . Administration tetanus vaccine within 6 month study vaccination . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . A family history congenital hereditary immunodeficiency . History neurologic disorder seizure . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine , plan use study period . History chronic alcohol consumption and/or drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>